David Shaw D.E. Shaw & Co
David Shaw founded D. E. Shaw & Co., a pioneering quantitative investment firm that helped define systematic trading at scale. With a background in computer science, Shaw built teams that applied advanced computation to markets across equities, derivatives, and other assets. The firm remains one of the most important quant platforms in global finance, even as Shaw’s own public role has shifted over time.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Pfizer
PFE
|
+$436M |
| 2 |
AbbVie
ABBV
|
+$407M |
| 3 |
Johnson & Johnson
JNJ
|
+$295M |
| 4 |
Gilead Sciences
GILD
|
+$267M |
| 5 |
Starbucks
SBUX
|
+$230M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Bristol-Myers Squibb
BMY
|
+$407M |
| 2 |
Booking.com
BKNG
|
+$400M |
| 3 |
Citigroup
C
|
+$314M |
| 4 |
SHPG
Shire pic
SHPG
|
+$276M |
| 5 |
PayPal
PYPL
|
+$257M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 17.04% |
| 2 | Healthcare | 13.44% |
| 3 | Consumer Discretionary | 13.38% |
| 4 | Financials | 7.19% |
| 5 | Industrials | 6.52% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
S
3201
CALL
DELISTED
Sprint Corporation
S
| $283K | ﹤0.01% |
+50,000
| New | +$310K |
|
|
EMKR
3202
DELISTED
Emcore Corp
EMKR
| $283K | ﹤0.01% |
+7,750
| New | +$330K |
|
|
LOVE
3203
LoveSac
LOVE
$233M
| $282K | ﹤0.01% |
+10,136
| New | +$275K |
|
3204
Everspin Technologies
MRAM
$429M
| $282K | ﹤0.01% |
36,805
+22,470
| +157% | +$164K |
|
3205
NVE Corp
NVEC
$517M
| $282K | ﹤0.01% |
2,877
| – | – |
|
3206
NewtekOne
NEWT
$360M
| $281K | ﹤0.01% |
+14,326
| New | +$278K |
|
3207
Savara
SVRA
$1.15B
| $281K | ﹤0.01% |
38,075
+23,346
| +159% | +$176K |
|
|
ACRE
3208
Ares Commercial Real Estate
ACRE
$262M
| $279K | ﹤0.01% |
18,380
-126,553
| -87% | -$1.84M |
|
3209
PUT
Axos Financial
AX
$5.61B
| $278K | ﹤0.01% |
9,600
| – | – |
|
3210
CALL
Teladoc Health
TDOC
$1.12B
| $278K | ﹤0.01% |
5,000
-3,600
| -42% | -$220K |
|
3211
PUT
WIX.com
WIX
$3.6B
| $278K | ﹤0.01% |
2,300
-2,200
| -49% | -$239K |
|
|
MRTX
3212
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
| $276K | ﹤0.01% |
3,763
-12,462
| -77% | -$848K |
|
3213
Coty
COTY
$2.35B
| $275K | ﹤0.01% |
+23,900
| New | +$226K |
|
3214
PUT
Belden
BDC
$4.57B
| $274K | ﹤0.01% |
5,100
-4,200
| -45% | -$230K |
|
3215
PUT
Ryder
R
$9.44B
| $273K | ﹤0.01% |
4,400
-91,400
| -95% | -$5.35M |
|
|
WW
3216
CALL
DELISTED
WW International
WW
| $272K | ﹤0.01% |
13,500
-67,600
| -83% | -$1.87M |
|
3217
Cognex
CGNX
$10.1B
| $270K | ﹤0.01% |
+5,310
| New | +$254K |
|
|
AAT
3218
American Assets Trust
AAT
$1.42B
| $269K | ﹤0.01% |
5,875
-4,081
| -41% | -$177K |
|
|
UNVR
3219
DELISTED
Univar Solutions Inc.
UNVR
| $268K | ﹤0.01% |
12,100
-119,542
| -91% | -$2.58M |
|
3220
Principal Financial Group
PFG
$23.9B
| $267K | ﹤0.01% |
5,324
-4,887
| -48% | -$242K |
|
3221
TriCo Bancshares
TCBK
$1.72B
| $267K | ﹤0.01% |
6,784
-2,762
| -29% | -$104K |
|
|
FNHC
3222
DELISTED
FedNat Holding Company Common Stock
FNHC
| $267K | ﹤0.01% |
16,652
+6,565
| +65% | +$119K |
|
|
DCOM
3223
DELISTED
Dime Community Bancshares
DCOM
| $267K | ﹤0.01% |
+14,280
| New | +$275K |
|
3224
CALL
Jabil
JBL
$32.3B
| $266K | ﹤0.01% |
10,000
| – | – |
|
|
ENT
3225
DELISTED
Global Eagle Entertainment Inc.
ENT
| $266K | ﹤0.01% |
15,018
+6,908
| +85% | +$393K |
|
Similar funds
David Shaw's Q1 2019 Portfolio in Review
As of Q1 2019, David Shaw held 4,169 positions worth $77.4B, up 6.6% from $72.6B the previous quarter. Its ten largest holdings account for 9% of the portfolio.
David Shaw withdrew a net $6.74B in Q1 2019, closing 617 positions and reducing 1,599 holdings. Its most notable exit was Shire pic, an estimated $276M position sold in full.
By sector, the portfolio is most concentrated in Technology at 17% of assets, up from 15% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, David Shaw opened a new position in Lyft worth $159M.
- David Shaw's largest Q1 2019 buy was Lyft: 2,245,851 shares worth $159M.
- David Shaw added most to Pfizer in Q1 2019, an estimated $436M increase.
- David Shaw's biggest Q1 2019 reduction was Bristol-Myers Squibb, cutting an estimated $407M.
- David Shaw fully exited Shire pic in Q1 2019, selling an estimated $276M.
- David Shaw's ten largest holdings make up 9% of its $77.4B portfolio in Q1 2019.
- David Shaw opened 447 new positions and closed 617 in Q1 2019.
- David Shaw's portfolio value rose 6.6% quarter-over-quarter to $77.4B.
Based on D.E. Shaw & Co's 13F filing for Q1 2019, filed 15 May 2019.